241 research outputs found
Weight evolution in patients after stavudine substitution for lipoatrophy in Rwanda: comparison of zidovudine with tenofovir/abacavir
Mexico AIDS Conference 200
Risk factors for hepatotoxicity of nevirapine-containing antiretroviral drug regimens in a large antiretroviral treatment program in Rwanda
Mexico AIDS Conference 200
Recommended from our members
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients.
Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical testing with modest reported antitumor effects [ 1]. The less-than-expected activity of these neoantigenic vaccines may correspond with the development of immune escape mechanisms. One permutation on neoantigen vaccines, which may counter or prevent these adaptive immune escape mechanisms, are 'personalized' oncolytic viruses that encode one or more tumor-specific transgenes. Herein, positive therapeutic effects for MY-NEOVAX™, personalized neoantigen-enhanced oncolytic adenoviruses, are described for two heavily pretreated end-stage patients, one with high-grade metastatic neuroendocrine carcinoma of the pancreas and the other with colorectal cancer metastatic to the brain, liver and lungs. To date, treatment benefit has exceeded 12 months without dose-limiting toxicities or related serious adverse events and with documented radiologic stabilization and improved performance status
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.
The goal of anticancer therapy is to selectively eradicate all malignant cells. Unfortunately for the majority of patients with metastatic disease, this goal is consistently thwarted by the nearly inevitable development of therapeutic resistance; the main driver of therapeutic resistance is a minority subpopulation of cancer cells called cancer stem cells (CSCs) whose mitotic quiescence essentially renders them non-eradicable. The Wnt signaling pathway has been widely implicated as a regulator of CSCs and, therefore, its inhibition is thought to result in a reversal of therapeutic resistance via loss of stem cell properties. RRx-001 is a minimally toxic redox-active epi-immunotherapeutic anticancer agent in Phase III clinical trials that sensitizes tumors to radiation and cytotoxic chemotherapies. In this article, as a potential mechanism for its radio- and chemosensitizing activity, we report that RRx-001 targets CD133 + /CD44 + cancer stem cells from three colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.
Small-cell lung cancer (SCLC), initially exquisitely sensitive to first-line cisplatin/etoposide, invariably relapses and acquires a multidrug chemoresistant phenotype that generally renders retreatment with first-line therapy both futile and counterproductive. This report presents the case of a 77-year-old Caucasian male with extensive-stage refractory SCLC who was restarted on platinum doublets as part of a clinical trial called TRIPLE THREAT (NCT02489903) involving pretreatment with the epi-immunotherapeutic agent RRx-001, and who achieved a partial response after only 4 cycles. The patient had received a platinum drug twice before, in 2009 for a diagnosis of non-small-cell lung cancer (squamous cell carcinoma) and in 2015 for SCLC, suggesting that RRx-001 pretreatment may sensitize or resensitize refractory SCLC patients to first-line chemotherapy
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters, neuromodulators and neuropeptides. Nevertheless, despite these common characteristics, NETs differ widely in terms of their natural histories: high-grade NETs are clinically aggressive and, like small cell lung cancer, which they most closely resemble, tend to respond to cisplatin and etoposide. In contrast, low-grade NETs, which as a rule progress and behave indolently, do not. In either case, the treatment strategy, apart from potentially curative surgical resection, is very poorly defined. This report describes the case of a 28-year-old white male with a diagnosis of high-grade NET of undetermined primary site metastatic to the lymph nodes, skin and paraspinal soft tissues, treated with the experimental anticancer agent RRx-001, in the context of a phase II clinical trial called TRIPLE THREAT (NCT02489903); serial sampling of tumor material through repeat biopsies demonstrated an intratumoral inflammatory response, including the amplification of infiltrating T cells, which correlated with clinical and symptomatic benefit. This case suggests that pseudoprogression or RRx-001-induced enlargement of tumor lesions, which has been previously described for several RRx-001-treated patients, is the result of tumoral lymphocyte infiltration
IMECE2003-44104 SIMULATION AND BOGIE TESTING OF A NEW CABLE BARRIER TERMINAL
ABSTRACT Roadside barriers of various designs are extensively used for the purpose of shielding obstacles along the road from impact with errant vehicles. One commonly applied roadside barrier system is a cable system, consisting of three steel cables supported by weak steel posts. Due to an increase in the use of cable systems, a tangent to the roadway, as opposed to flared away from the roadway, crashworthy end terminal has been designed by the Midwest Roadside Safety Facility. The design goal was to effectively disengage the pre-tensioned cables at the end anchor point when impacted on the end by a vehicle, allowing the vehicle to pass through the system virtually unobstructed. It is the objective of this study to help evaluate the new design through bogie testing and nonlinear finite element analysis using LS-DYNA. Based on bogie test results and detailed analysis of the simulation results, it was concluded that the new cable end terminal was ready for full-scale crash testing. INTRODUCTION Roadside barriers of various designs are extensively used for the purpose of shielding obstacles along the road from impact with errant vehicles. One commonly applied roadside barrier system is the 3-strand cable system. This system consists of three steel cables supported by weak steel posts. The steel cables are pre-tensioned with a specified initial load, and are anchored at both ends of the system. When an errant vehicle obliquely impacts the 3-strand cable system, sufficient tension is developed within the cables to redirect the vehicle, effectively shielding the roadside hazard and increasing the safety of the vehicle operator. The weak steel posts supporting the cables offer very little resistance to the impacting vehicle. Due to the likelihood of a longitudinal impact with the end of the 3-strand cable system, a crashworthy end terminal has been designed by the Midwest Roadside Safety Facility (MwRSF). The design goal was to effectively disengage the pre-tensioned cables at the end anchor point upon impact with a vehicle, allowing the vehicle to pass through the system virtually unobstructed. To assist in the development of the 3-strand cable system end terminal, the CTB-4 bogie crash test was conducted. It is the objective of this study to simulate the cable terminal bogie test CTB-4 using LS-DYNA, a nonlinear finite element analysis code (1), and validate the simulation results with that of the physical test
Navigating the “No Man\u27s Land” of TKI-Failed EGFR-Mutated Non– Small Cell Lung Cancer (NSCLC): A Review
As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue that is overwhelmingly caused by smoking. However, a substantial minority (~25%) of patients with non–small cell lung cancer (NSCLC) has never smoked. In these patients, activating mutations of the epidermal growth factor receptor (EGFR) are more likely, which render their tumors susceptible for a finite period to treatment with EGFR tyrosine kinase inhibitors (TKIs) and confer a better prognosis than EGFR wild-type NSCLC. On progression, due to the inevitable insurgence of resistance, TKIs are generally followed by second- or third-line salvage chemotherapy until treatment failure, after which no standard treatment options are available, resulting in a poor prognosis and a high risk of death. With the focus of clinical attention on treatment with TKIs, few studies on optimal salvage therapies, including cytotoxic chemotherapy, after failure of EGFR TKIs have been reported. Despite a paucity of available data, the aim of this review is to summarize the “no-man\u27s land” of TKI-failed EGFR-mutated NSCLC and expand on alternative strategies as well as potential future directions
No patient left behind : The promise of immune priming with epigenetic agents
Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually benefit from treatment. Emerging evidence implicates epigenetic alterations as a mechanism of clinical resistance to immunotherapy. This review presents evidence for that association, summarizes the epi-based mechanisms by which tumors evade immunogenic cell death, discusses epigenetic modulation as a component of an integrated strategy to boost anticancer T cell effector function in relation to a tumor immunosuppression cycle and, finally, makes the case that the success of this no-patient-left-behind strategy critically depends on the toxicity profile of the epigenetic agent(s).Peer reviewe
- …